Sugimura A, Kanatsuka H, Tanikawa T, Ong B H, Shirato K
The First Department of Internal Medicine, Tohoku University, School of Medicine, Sendai, Japan.
Jpn Circ J. 2000 Nov;64(11):868-75. doi: 10.1253/jcj.64.868.
Diadenosine tetraphosphate (AP4A) can be released from activated platelets and the present study examined its effect on coronary arterial microvessels. The role of purinoceptors in the coronary microcirculation in vivo was also investigated. In open chest dogs, coronary arterioles were observed using a microscope with a floating objective. In Protocol 1, AP4A (1, 10, 100 and 1,000 micromol/L) was superfused onto the heart surface before and during the superfusion of 10 micromol/L of 8-phenyltheophylline (8-PT), a P1 purinoceptor blocker. In Protocol 2, AP4A (0.1, 1, 10, and 100 nmol x kg(-1) x min(-1)) was infused into the left anterior descending coronary artery before and during the superfusion of 10 micromol/L of 8-PT. In addition to 8-PT, 30 micromol/L of pyridoxalphosphate-6-azophenyl 2',4'-disulphonic acid (PPADS), a P2X purinoceptor blocker in Protocol 3, or 300 micromol/L of N(omega)-nitro-L-arginine (LNNA) in Protocol 4, was continuously superfused, and 4 doses of AP4A were cumulatively superfused as in Protocol 1. In Protocol 5, 10 micromol/L of alpha,beta-methylene ATP, an agonist of P2X purinoceptors, was superfused for 60 min. Superfused AP4A dilated arterioles in a dose-dependent manner. The magnitude of dilatation was greater in smaller arterioles (small vessel < or = 150 microm: 24.5+/-2.2% vs large vessel > 150 microm: 10.6+/-1.5% at a dose of 1,000 micromol/L, p<0.001). On the other hand, intraluminally applied AP4A also dilated arterioles, but no size dependency was shown. In the presence of 8-PT, vasodilatory responses to superfused and intraluminally applied AP4A were attenuated and the lower doses of AP4A constricted arterioles. This vasoconstrictor effect was not affected by PPADS. The vasodilatory effect of the higher doses of AP4A was almost abolished in the presence of LNNA. Alpha,beta-methylene ATP had no effect on coronary microvascular diameters. AP4A has bidirectional effects on coronary arterial microvessels: vasodilatory effects mediated by P1 purinoceptors and NO, which might be mediated by P2Y purinoceptors, and a vasoconstrictor effect, which is not mediated by P2X purinoceptors.
四磷酸二腺苷(AP4A)可从活化的血小板中释放出来,本研究检测了其对冠状动脉微血管的影响。同时还研究了嘌呤受体在体内冠状动脉微循环中的作用。在开胸犬身上,使用带有浮动物镜的显微镜观察冠状动脉小动脉。在方案1中,在灌注10 μmol/L的P1嘌呤受体阻滞剂8-苯基茶碱(8-PT)之前和期间,将AP4A(1、10、100和1000 μmol/L)灌注到心脏表面。在方案2中,在灌注10 μmol/L的8-PT之前和期间,将AP4A(0.1、1、10和100 nmol·kg⁻¹·min⁻¹)注入左前降支冠状动脉。除了8-PT,在方案3中持续灌注30 μmol/L的P2X嘌呤受体阻滞剂磷酸吡哆醛-6-偶氮苯-2',4'-二磺酸(PPADS),或在方案4中持续灌注300 μmol/L的N(ω)-硝基-L-精氨酸(LNNA),并如方案1那样累积灌注4剂AP4A。在方案5中,灌注10 μmol/L的P2X嘌呤受体激动剂α,β-亚甲基ATP 60分钟。灌注的AP4A以剂量依赖性方式使小动脉扩张。在较小的小动脉中扩张幅度更大(小血管≤150 μm:在1000 μmol/L剂量时为24.5±2.2%,而大血管>150 μm:为10.6±1.5%,p<0.001)。另一方面,腔内应用AP4A也使小动脉扩张,但未显示出大小依赖性。在存在8-PT的情况下,对灌注和腔内应用AP4A的血管舒张反应减弱,且较低剂量的AP4A使小动脉收缩。这种血管收缩作用不受PPADS影响。在存在LNNA的情况下,较高剂量AP4A的血管舒张作用几乎被消除。α,β-亚甲基ATP对冠状动脉微血管直径无影响。AP4A对冠状动脉微血管有双向作用:由P1嘌呤受体和一氧化氮介导的血管舒张作用,这可能由P2Y嘌呤受体介导,以及一种不由P2X嘌呤受体介导的血管收缩作用。